Esperion Therapeutics, Inc. (ESPR) AI-Powered Stock Analysis
See how Esperion Therapeutics, Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
ESPR●NASDAQ
HealthcareBiotechnology
$3.18
$0.010(0.31%)
U.S. Market opens in 44h 3m
Advertisement
Esperion Therapeutics, Inc. (ESPR)
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerEsperion Therapeutics, Inc. (ESPR) Stock Overall Grade
Esperion Therapeutics, Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Esperion Therapeutics, Inc.'s overall stock rating.
Forecast
C+Score
55/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
59/100Key Ratios
C+Score
57/100Sector Comparison
AScore
85/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Esperion Therapeutics, Inc. (ESPR) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 55/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (59/100, C+) highlight its stability, while Key Ratios (57/100, C+) and Sector Comparison (85/100, A) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Esperion Therapeutics, Inc. stock grade, including financials, comparisons, and forecasts.